SunTrust Banks, Inc. restated their buy rating on shares of Amedisys Inc (NASDAQ:AMED) in a research report report published on Monday. SunTrust Banks, Inc. currently has a $60.00 price target on the health services provider’s stock.
Other equities research analysts have also recently issued research reports about the stock. Mizuho cut shares of Amedisys from a buy rating to a neutral rating and set a $50.00 target price on the stock. in a report on Wednesday, July 26th. BidaskClub cut shares of Amedisys from a strong-buy rating to a buy rating in a report on Wednesday, July 12th. Robert W. Baird reissued a hold rating and set a $50.00 target price on shares of Amedisys in a report on Wednesday, October 4th. Oppenheimer Holdings, Inc. reissued a buy rating and set a $60.00 target price on shares of Amedisys in a report on Friday, September 15th. Finally, Bank of America Corporation initiated coverage on shares of Amedisys in a report on Monday, August 21st. They set a neutral rating and a $55.00 target price on the stock. Seven research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $56.20.
Amedisys (NASDAQ AMED) opened at 47.80 on Monday. Amedisys has a 52 week low of $34.58 and a 52 week high of $65.91. The company has a market cap of $1.62 billion, a price-to-earnings ratio of 40.85 and a beta of 0.87. The stock’s 50 day moving average price is $51.87 and its 200-day moving average price is $55.14.
Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 EPS for the quarter, beating the consensus estimate of $0.50 by $0.12. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The business had revenue of $378.80 million for the quarter, compared to the consensus estimate of $380.80 million. During the same quarter in the prior year, the business earned $0.42 earnings per share. Amedisys’s revenue for the quarter was up 5.0% on a year-over-year basis. On average, equities research analysts forecast that Amedisys will post $2.21 earnings per share for the current fiscal year.
WARNING: This story was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/2957421/amedisys-inc-amed-stock-rating-reaffirmed-by-suntrust-banks-inc.html.
In other news, Director Bruce D. Perkins purchased 2,000 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The shares were purchased at an average price of $46.60 per share, with a total value of $93,200.00. Following the completion of the acquisition, the director now owns 15,825 shares in the company, valued at approximately $737,445. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, insider David B. Pearce sold 1,000 shares of the company’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the completion of the transaction, the insider now directly owns 10,488 shares in the company, valued at approximately $524,400. The disclosure for this sale can be found here. Insiders own 2.00% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in AMED. Russell Investments Group Ltd. increased its holdings in shares of Amedisys by 77.7% in the first quarter. Russell Investments Group Ltd. now owns 36,295 shares of the health services provider’s stock worth $1,854,000 after purchasing an additional 15,875 shares during the period. Comerica Bank increased its holdings in shares of Amedisys by 4.2% in the first quarter. Comerica Bank now owns 30,909 shares of the health services provider’s stock worth $1,670,000 after purchasing an additional 1,258 shares during the period. Swiss National Bank increased its holdings in shares of Amedisys by 1.8% in the first quarter. Swiss National Bank now owns 44,300 shares of the health services provider’s stock worth $2,263,000 after purchasing an additional 800 shares during the period. UBS Asset Management Americas Inc. increased its holdings in shares of Amedisys by 140.0% in the first quarter. UBS Asset Management Americas Inc. now owns 11,760 shares of the health services provider’s stock worth $601,000 after purchasing an additional 6,861 shares during the period. Finally, Karp Capital Management Corp bought a new position in shares of Amedisys in the first quarter worth $683,000. 96.55% of the stock is currently owned by hedge funds and other institutional investors.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.